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Abstract Tuberculosis meningitis (TBM) is the most
severe form of extra-pulmonary tuberculosis and is par-
ticularly intense in small children; there is no universally
accepted algorithm for the diagnosis and substantiation of
TB infection, which can lead to delayed intervention, a
high risk factor for morbidity and mortality. In this study a
proton magnetic resonance (1H NMR)-based metabolomics
analysis and several chemometric methods were applied to
data generated from lumber cerebrospinal fluid (CSF)
samples from three experimental groups: (1) South African
infants and children with confirmed TBM, (2) non-men-
ingitis South African infants and children as controls, and
(3) neurological controls from the Netherlands. A total of
16 NMR-derived CSF metabolites were identified, which
clearly differentiated between the controls and TBM cases
under investigation. The defining metabolites were the
combination of perturbed glucose and highly elevated
lactate, common to some other neurological disorders. The
remaining 14 metabolites of the host’s response to TBM
were likewise mainly energy-associated indicators. We
subsequently generated a hypothesis expressed as an
‘‘astrocyte–microglia lactate shuttle’’ (AMLS) based on the
host’s response, which emerged from the NMR-meta-
bolomics information. Activation of microglia, as implied
by the AMLS hypothesis, does not, however, present a
uniform process and involves intricate interactions and
feedback loops between the microglia, astrocytes and
neurons that hamper attempts to construct basic and linear
cascades of cause and effect; TBM involves a complex
integration of the responses from the various cell types
present within the CNS, with microglia and the astrocytes
as main players.
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Tuberculosis (TB), one of the major contemporary pan-
demics, is caused by Mycobacterium tuberculosis (Mtb);
its worldwide impact remains a serious concern. The dis-
ease in children is particularly severe as diagnosis is dif-
ficult since its identification in children usually results from
a combination of, often asymptomatic, clinical criteria,
non-specific TB tests and diagnostic markers, all of which
have a low sensitivity and specificity (van Well et al.
2009), leading to delayed intervention, and a high risk of
morbidity and mortality. According to the WHO Global TB
Report for 2012 (WHO 2013), there were approximately
325,000 clinically defined new cases of TB in South Africa
alone, of which 42,000 (14 %) were of the extra-pulmonary
forms (EPTB). Central nervous system (CNS) TB accounts
for an estimated 1–10 % of all EPTB (Cherian and Thomas
2011; Bhigjee et al. 2007; Rock et al. 2005), with tuber-
culous meningitis—also known as TB meningitis (TBM)—
being not only the most severe complication of the disease
but also the most common form of bacterial meningitis
(BM) in South African children (Wolzak et al. 2012).
Infants and young children are particularly prone to dis-
semination of TB, especially TBM, due to their young age
and immature immune systems. Most TBM patients upon
admission present with an advanced stage of disease due to
difficulty of diagnosis in the early stages, resulting in an
estimated 30 % of patients dying despite treatment (You-
ssef et al. 2006).
Cerebrospinal fluid (CSF) is the biofluid that is in direct
contact with the site of TBM infection and contains a
wealth of information potentially useful for TBM diagnosis
and treatment. Evaluation of the characteristics of CSF is
already a key factor in the diagnosis of several CNS dis-
eases (Seehusen et al. 2003; Watson and Scott 1995),
particularly of TBM (van Well et al. 2009). CSF from
TBM cases typically shows a clear appearance, moderate
pleocytosis with a predominance of lymphocytes, increased
protein content and a very low glucose concentration
(Principi and Esposito 2012). To improve on these general
clinical observations, more sophisticated clinical-chemistry
tests on CSF have been proposed but none with elevated
sensitivity and specificity (Ho et al. 2013), although
potentially useful to support the diagnosis in some cases
(Principi and Esposito 2012). Improved clinical outcomes
are highly dependent on timely diagnosis and initiation of
appropriate treatment for survival benefit (Ruslami et al.
2013), leaving monitoring of treatment likewise a key
developmental need for this complex infectious disease, to
which an untargeted metabolomics investigation could
make a distinct contribution, as shown in this paper.
Metabolomics information has the advantage of being
context dependent by disclosing the complement of
metabolites associated with a physiological, developmen-
tal, or pathological state prevailing in a cell, tissue, organ,
or organism. Infection of the Mtb bacilli occurs through
inhalation of aerosolized droplets and harbouring of the
bacilli in the pulmonary system. Should dissemination into
the lympho-hematogenous circulatory system occur
(Krishnan et al. 2010; El-Kebir et al. 2013), the brain
becomes a very attractive site for the establishment of
metastatic foci due its rich vascular and oxygen supply.
Mtb appears to enter the subarachnoid space via rupture of
an adjacent parenchymal tubercle (Leonard and Des Prez
1990) and CD14 receptors of the microglia may render
them as the principal cell target in the CNS (Peterson et al.
1995). Microglial cells are the resident macrophages of the
brain parenchyma; they share many, if not all, of the
properties of macrophages in other tissues (Nareika et al.
2005), such as production of a variety of cytokines and
chemokines on activation. Despite this hostile bactericidal
environment, it provides protection and shelter to Mtb from
other immune cells and promotes development of small
tuberculous foci, commonly known as granulomas (Ernst
1998; Davis and Ramakrishnan 2009), presenting one of
the ultimate paradoxes in the study of TBM host–pathogen
interactions (Thi et al. 2012).
A unique aspect of TB in children is the unnoticed
infection by Mtb in the often rapid development of the dis-
ease (Swaminathan and Rekha 2010), usually in children
younger than 5 years and/or in HIV-infected children
(Starke 2003). The outcome of TBMcorrelateswith the stage
at which disease treatment starts, underlining the need for
early detection and a prompt clinical response. Metabolo-
mics proved to be suited for a powerful global study of dis-
eases of the human CNS, with the potential of mapping early
biochemical changes in these diseases, providing opportu-
nities for timely diagnosis and development of signatures
and hence for assisting in effective interventions (Dunne
et al. 2005; Kaddurah-Daouk and Krishnan 2009; Madsen
et al. 2010; Sinclair et al. 2009). The systematic character-
ization of the CSF metabolome is well established with
contributions coming from studies using various platforms
(Guo et al. 2011; Mandal et al. 2012; Stoop et al. 2010;
Wevers et al. 1995; Wishart et al. 2008). To date, the pre-
sence of 476 detectable metabolites with an extensive
dynamic range has been confirmed in the human CSF
metabolome, of which 170 are readily measurable, 75 have
concentrations above 1 lM and 47 metabolites have been
quantified by NMR by Wishart et al. (2008). Due to its
hydrophilic nature, NMRcan be considered the best platform
for characterizing CSF. Major challenges for investigations
of the CSF metabolome are (1) the diverse nature and low
concentrations ofmetabolites, (2) limited availability and (3)
small sample volumes (Guo et al. 2011; Stoop et al. 2010), as
a result of ethical issues, such as pain and health risks, that
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restrict the general availability of CSF for research purposes
(Geiszler et al. 2013). To date, NMR-based metabolomics of
TB has been conducted on infected mice (Shin et al. 2011),
guinea pigs (Somashekar et al. 2011) and humans (Zhou et al.
2013), on other forms of meningitis (Coen et al. 2005;
Himmelreich et al. 2009) and a study by Subramanian et al.
(2005), which selected 12 CSF metabolites for differential
diagnosis of meningitis in children through in-house soft-
ware diagnostics.
The focus of the NMR metabolomics study of CSF
reported here is directed towards the host’s metabolic
response to the TBM infection. The unusually high inci-
dence of TB in childhood in isolated regions in the Western
Cape province of South Africa provided a unique oppor-
tunity to obtain CSF samples for a metabolomics study
based on a cohort of infants and small children definitively
diagnosed with TBM. Two control groups were likewise
used in this investigation: the first consisted of South
African infants and children initially suspected to be suf-
fering from meningitis (but subsequently shown to be
negative), and secondly, control samples from an unrelated
neurological study in the Netherlands. The outcome of this
NMR investigation revealed metabolic perturbations due to
TBM, and has considerable potential for improving the
early clinical assessment of the disease state in TBM and
for monitoring responses to treatment regimes. The meta-
bolic profile also contributed to hypothesis formulation,
proposed as an ‘‘astrocyte–microglia lactate shuttle’’
(AMLS), encapsulating the unique metabolic plasticity in
the CNS metabolism towards the energy requirements for
the microglia-driven neuroinflammatory responses, of
which TBM may be one such example.
2 Materials and methods
2.1 Experimental design
Metabolic fingerprinting of NMR data requires pre-pro-
cessing to generate a data matrix of variables and cases of
an operational size, to be followed by multivariate analysis
to identify the relevant analytical information. The work
flow that we followed is shown schematically in Fig. 1.
Our selected experimental group consisted of 33 children
with confirmed TBM and two control groups, as described
below. Untargeted 1H NMR analysis of CSF samples
yielded spectra that were resolved into 110 buckets of
variable size. Following removal of outliers from the
patient and two control groups, the important, known
metabolites observed in the TBM-infected cases were
identified and cross-validated by statistical modelling. The
16 NMR-derived metabolites differentiating TBM from
non-TBM, based on this South African cohort of patients,
were then quantified, compared to normal reference ranges
and the corresponding biological interpretation given, from
which our hypothesis was generated.
2.2 Sample collection, description and storage
The three experimental groups used in this study were: (1)
South African patients with confirmed TBM (see compre-
hensive description of clinical profiles in section S1, Table
S1 and Table S2 of the Supplementary Information (SI), and
on the medication used for treatment in Table S3); (2) non-
meningitis South African controls (SA_Controls); and (3)
neurological controls from the Netherlands (NL_Controls).
The first two groups comprised children between the ages of
6 months and 12 years, all of whom were originally sus-
pected meningitis cases and referred from local clinics to the
paediatrics unit at Tygerberg Hospital in the Western Cape
Fig. 1 Schematic representation of the work flow following data
generation, based on statistical pre-processing, data analysis and
cross-validation to identify important NMR-derived metabolites of
TBM infection
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province of South Africa. In most of these cases, a broad
range of non-specific treatments (e.g., broad-spectrum anti-
biotics, analgesics and anti-inflammatories) were initiated
prior to admission. These individuals were given a thorough
assessment by a paediatric neurologist at Tygerberg Hospi-
tal, which involved an extensive description of the clinical
background, including polymerase chain reaction and cul-
ture analysis of a CSF sample obtained through a lumbar
puncture. The main physical presentations and clinical
symptoms of these cases, as testified by parents and observed
by the respective clinicians, were compatible with non-CNS
indications of TB outside the CNS, typically observed in
small TB-infected children from the region. As part of the
diagnostic process a detailed inspection of the clinical
chemistry of the CSF was conducted and yielded a report
describing the count and type of cells present, particularly
immune response-related cells (Table S2), as well as a
measure of CSF protein (mostly high:[1 g/L) and glucose
(mostly low:\2.2 mmol/L or CSF:blood glucose
ratio\50 %) levels. The South African controls were con-
firmed negative for any form of meningitis, despite being ill
with symptoms reminiscent of the condition. Ethical and
practical considerations limited the availability of healthy
controls, which could partially be overcome through a
comparative analysis of a second control group with CSF
collected from untreated individuals from the Radboud
University Medical Centre in Nijmegen, the Netherlands.
The Netherlands non-TBM control group (the third experi-
mental group) consists of CSF samples from age-matched
patients whowere suspected to suffer from a neurometabolic
disease. After appropriate and in depth investigations no
clinical or biochemical evidence was found for such diag-
nosis in any of these patients. The only disease exclusion
criterion applied to all cases was HIV co-infection.
The present study was approved by the Human Research
Ethics Committee of Stellenbosch University, South Africa
(study nr. N11/01/006).
2.3 Sample preparation and 1H NMR spectroscopy
All CSF samples were stored at-80 C prior to analysis and
transported to the NMR facility at the Laboratory for
Genetic, Endocrine and Metabolic Diseases at the Radboud
University Medical Centre in Nijmegen, where the NMR
analyses were conducted. Sample preparation followed the
standard operating procedure as established by theNijmegen
laboratory (Engelke et al. 2005, 2006; Wevers et al. 1995).
Each CSF sample was measured at 500 MHz on a
Bruker DRX Avance spectrometer equipped with a triple-
resonance inverse probe head. Software used was: Bruker
Topspin (V3.1) for data pre-processing and Bruker AMIX
(V3.9.12) for binning and quantification (Ellinger et al.
2013). Variable-sized bucketing was used to create a data
matrix of 110 variables, followed by log transformation.
The NMR region representing the suppressed water signal
(4.67–4.96 ppm) was excluded from the data matrix. A
more detailed description of the NMR protocol and pre-
treatment of the original NMR-data are included in section
S2 and S3, respectively, of the SI.
2.4 Statistical analyses
The original TBMgroupwas slightly reduced by excluding 4
cases which were older than 5 years of age, intended to
define a more homogeneous group of infants and children.
Unsupervised principal component analysis (PCA) and
Hotelling’s T2 test, with a confidence level of 95 %,was used
to remove further case outliers for each experimental group;
assessment of overall variance of variables was used to
remove variable outliers. The multivariate analyses (see
Fig. 1) were done using the statistical software package The
Unscrambler X (V10.3, CAMO software AS, Norway),
successfully applied in other metabolomics studies (e.g.,
Maddula and Baumbach 2011). Supervised partial least
squares-discriminant analysis (PLS-DA) modelling was
used to identify the important variables and cross-validated
by leaving one sample out at a time, using the same samples
for model estimation and testing. The principal advantage of
this leave-one-out cross-validation is that it is an efficient
method of dealing with a small number of cases (as is typi-
cally the situation with metabolomics data) and allows for
the jack-knifing approach on which an uncertainty test is
based. The uncertainty test creates a number of sub-models
on all the samples not kept in the cross-validation segment;
for every sub-model the variations are estimated to assess the
stability of the results and an overall p value is output per
validated variable based on the PLSmodel. Following this, a
regressionmodel is given that plots the predictedY-values of
the PLSmodel for all samples, together with a deviation that
expresses the uncertainty of the prediction. The deviations
are estimated as a function of the global model error, the
sample leverage, and each sample’s residual X-variance. A
small deviation indicates that the sample used for prediction
is similar to the samples used for the calibration model,
whereas predicted Y-values with high deviations are less
reliable. This predicted regression model is used to assess
how well the PLS model is able to correctly classify cases as
TBM or non-TBM.
The online metabolomics suite, Metaboanalyst 2.0
(www.metaboanalyst.ca) (Xia et al. 2009), was used to
create the quantitative VIP values [Variables Important in
Projection (VIP) are conventionally used in metabolomics
studies to identify important metabolites] for the PLS-DA
analyses, as well as to calculate the univariate measures
[fold change (d-values) and t test (p values)] for the final
reduced data matrix.
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3 Results and discussion
3.1 Data analysis and identification of important
variables
A representative NMR spectrum, covering the region
0.80–4.80 ppm and scaled relative to the internal standard
peak (TSP), from each of the three experimental groups
used, is given in Fig. 2. This section of the spectrum serves
to illustrate some of the discernible qualitative NMR dif-
ferences associated with the CSF taken from the TBM-
infected infants and small children compared to non-TBM
cases. Not shown in Fig. 2 are assignments attributed to
medication found within the aromatic region of the spectra
(6–9 ppm) from treated individuals, which were identified
by comparison with spectra corresponding to the pure
Fig. 2 1H 500 MHz NMR spectra of CSF at pH 2.5 scaled according
to internal standard peak (TSP) illustrating qualitative differences
between single examples of untreated NL_Control (top), treated
SA_Control (middle) and TBM cases (bottom). [Assignments (ppm):
1 isoleucine/leucine (0.94t/0.95d), 2 valine/isoleucine (1.00d/1.01d),
3 valine (1.04d), 4 propylene glycol (1.13d), 5 ethanol (1.17d, 3.64q),
6 3-hydroxybutyrate (1.23d, 2.53q), 7 13C lactate (1.30d, 1.52d), 8
threonine/3-hydroxyisovalerate (1.33d/1.33s), 9 lactate(1.41d, 4.36q),
10 alanine (1.51d), 11 pyruvate (1.56s, 2.37s), 12 lysine (1.73 m), 13
unknown, 14 acetate (2.08s), 15 glutamine (2.16m, 2.47m), 16
acetone (2.22s), 17 citrate (2.91AB), 18 creatine (3.05s, 4.10s), 19
creatinine (3.13s, 4.29s), 20 choline (3.19s), 21 glucose (3.23dd,
3.3–3.9, 4.64d, 5.22d), 22 betaine/myo-inositol (3.27s/3.27t), 23 myo-
inositol (4.05t)]. Multiplicity of peak(s): s singlet, d doublet, dd
double duplet, t triplet, q quartet, m multiplet, AB AB system
Fig. 3 PCA scores plot of SA_Controls vs TBM (a) and NL_Controls vs TBM (b), showing natural separation between TBM and non-TBM
cases
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compounds, as well as unassigned peaks that have yet to be
identified.
Case and variable reduction was followed as described
in Fig. 1. Unsupervised PCA of all 3 experimental groups
separated the TBM cases and both control groups, with
some overlap between the control groups indicating that
they shared similar characteristics but were not homoge-
neous (see Fig. S1). PCA of the SA_Controls vs TBM
(Fig. 3a) and NL_Controls vs TBM (Fig. 3b) cases further
illustrates the natural separation between TBM and non-
TBM. Quantitatively, the two metabolites that yielded the
greatest power values based upon PCA (i.e., those most
responsible for the separation) were highly elevated lactate
and decreased glucose in the TBM cases relative to normal
reference values for CSF glucose (see Table S4).
In order to focus on the biological/metabolic informa-
tion we subdivided the data matrix into three classes of
variables, namely: (1) known endogenous compounds, (2)
medications (exogenous), and (3) unassigned variables. To
determine the more subtle characteristics that distinguish
the host metabolic profile of TBM we selected the known
endogenous variables (classifiable as metabolites), which
could be confidently assigned given the highly specific
nature of NMR technology, and in addition removed the
two dominating metabolites—lactate and glucose. This
filtering resulted in a reduction of the data matrix under
analysis from 109 to 40 variables.
Supervised PLS-DA modelling was performed on the
reduced data set for both the SA_Controls vs TBM and
NL_Controls vs TBM cases as shown in Fig. 4. The
regression model identified the important variables, marked
in the corresponding correlation loadings plots, which were
then cross-validated and used in a regression prediction
with deviation that illustrates—for the SA_Controls vs
TBM case (Fig. 4b) and in the NL_Controls vs TBM case
(Fig. 4d)—that there is good case classification. The R2
and Q2 values for the NL_Controls vs TBM case were 0.80
and 0.77 respectively, while the R2 and Q2 values for the
SA_Controls vs TBM case were 0.90 and 0.83, respec-
tively. The fundamental requirement for PLS to yield
meaningful information is the ability to select variables. In
our case this is done quantitatively on the basis of the VIP
value, which, together with other meaningful univariate
quantitative measures (fold change d-values and t test
p values), are given in Table 1. Based upon a selection
criterion of VIP[ 1.0, and taking the univariate measures
into consideration, we were able to select 8 significant
metabolites common to both cases, namely: myo-inositol,
creatinine, dimethyl sulfone and several amino acids
[lysine, alanine and three branched-chain amino acids
(BCAAs): valine, isoleucine and leucine]. Using the same
selection criteria, phenylalanine and tyrosine are uniquely
important when comparing the NL_Controls vs TBM case,
whereas choline, formate, acetate, citrate and pyruvate are
uniquely important to the SA_Controls vs TBM case.
Ethanol manifested as important in the NL_Controls vs
TBM case but, although very small amounts of ethanol are
produced endogenously by bacteria through anaerobic
fermentation, it is likely that its presence was due to con-
tamination from skin disinfection prior to lumbar puncture
(Fig. 5).
Thus a total of 16 NMR-derived CSF metabolites, which
differentiated between the South African TBM cases under
investigation and controls, were selected for quantification
in the 17 TBM, 19 SA_Control and 30 NL_Control cases
and the outcome compared to their normal reference ranges
for human CSF (summarized output presented in Table 2).
3.2 Brain energy metabolism and the response to TBM
The clear and defining metabolites distinguishing the TBM
cases under investigation from the control groups were the
combination of perturbed glucose and highly elevated
lactate, which is in line with the clinical characteristics of
CSF from patients with BM and TBM (Leib et al. 1999)
and is generally accepted as a key indication of distur-
bances in energy metabolism of many neurological disor-
ders (Leen et al. 2012). Regional variation and the
complement of cellular determinants participating in a
synchronised way is a unique characteristic of neurological
energy production. It has thus been proposed that the
microvascular endothelium of the blood–brain barrier
(BBB), astrocytes, neurons and extracellular matrix con-
stitute a ‘‘neurovascular unit’’, which is essential to normal
CNS physiology and health (reviewed by Hawkins and
Davis 2005).
A basic functional component in this unit is the meta-
bolic astrocyte–neuron coupling. The astrocytes participate
through glutamate-stimulated aerobic glycolysis, resulting
in the release of lactate, thereby serving as fuelling in
conditions of an activity-dependent neuronal energy
demand (Magistretti and Pellerin 1999). Several experi-
ment-based insights (reviewed by Pellerin and Magistretti
2003 and Pellerin and Magistretti 2004) lend empirical
support to the original proposed ‘‘astrocyte–neuron lactate
shuttle’’ model on energy transfer in the CNS (Bittar et al.
1996; Pellerin et al. 1998). Recent views highlight the
importance of brain endothelial cells in the modular
organization of the neurovascular unit (Abbott et al. 2006)
and summarize how several pathologies of the CNS may be
involved in the disturbance of this organization, including
Fig. 4 PLS scores plot and corresponding correlation loadings with
marked important variables of SA_Control vs TBM (a) and NL_Con-
trols vs TBM (c) reduced cases. The regression prediction plot
illustrates that the PLS model classifies the cases correctly in the
SA_Control vs TBM (b) and NL_Control vs TBM (d) cases
c
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Table 1 Quantitative statistical data indicating the important metabolites that discriminate between TBM and non-TBM for both SA_Controls
vs TBM and NL_Controls vs TBM cases with dominating metabolites lactate and glucose removed
PLS t test Fold change Validation
(VIP value) (p value) (d-value) (p value)
SA_Controls vs TBM
Choline (3.19) 1.810 \0.001 0.263 \0.001
Alanine (1.51) 1.793 \0.001 0.344 \0.001
Myo-inositol (3.285) 1.708 \0.001 1.605 0.007
Creatinine (3.13) 1.654 \0.001 1.689 \0.001
Lysine (1.73) 1.611 \0.001 0.601 \0.001
Valine/isoleucine (1.01) 1.580 \0.001 0.409 \0.001
Valine (1.04) 1.514 \0.001 0.417 \0.001
Acetate (2.08) 1.371 \0.001 1.635 0.224
Myo-inositol (4.05) 1.338 0.001 1.478 0.366
DMSO2 (3.14) 1.110 0.005 1.809 0.072
Formate (8.25) 1.089 0.006 0.651 \0.001
Pyruvate (1.56) 1.083 0.007 0.632 0.001
Citrate (2.81) 1.044 0.009 1.245 0.616
Isoleucine/leucine (0.95) 1.042 0.009 0.715 \0.001
Pyruvate (2.37) 1.011 0.012 0.668 0.005
Tyrosine (7.19) 0.979 0.015 0.688 \0.001
2-Oxoglutarate (2.68) 0.977 0.015 0.511 0.007
Phenylalanine/medication (7.42) 0.947 0.019 0.666 \0.001
Citrate (2.84) 0.944 0.019 1.224 0.838
Threonine (1.34) 0.895 0.027 0.727 \0.001
Creatinine (4.29) 0.891 0.028 1.176 0.185
Creatine (3.05) 0.886 0.029 0.832 \0.001
Phenylalanine (7.39) 0.790 0.053 0.681 0.010
Creatine (4.10) 0.751 0.067 1.230 0.500
Glutamine (2.47) 0.747 0.068 1.098 0.233
Succinate (2.66) 0.699 0.089 0.671 0.016
Acetone (2.22) 0.576 0.164 1.763 0.617
Mannose (5.17) 0.530 0.202 1.626 0.422
Ethanol (3.64) 0.516 0.214 1.145 0.877
Tyrosine/medication (6.90) 0.512 0.218 0.873 0.125
Acetoacetate (2.30) 0.421 0.312 0.951 0.178
Citrate (2.97) 0.367 0.380 1.062 0.327
Glutamine/medication (2.16) 0.287 0.492 1.049 0.090
Ethanol (1.18) 0.237 0.572 1.013 0.491
Betaine/myo-inositol (3.27) 0.202 0.630 0.949 0.002
3-Hydroxybutyrate (2.53) 0.198 0.636 0.999 0.374
3-Hydroxyisovalerate/threonine (1.33) 0.113 0.789 0.949 0.003
Citrate (3.00) 0.083 0.843 0.995 0.002
Carnitine (3.22) 0.031 0.940 0.952 0.026
3-Hydroxybutyrate (1.23) 0.018 0.965 1.123 0.882
NL_Controls vs TBM
Alanine (1.51) 1.986 \0.001 0.299 \0.001
Valine (1.04) 1.961 \0.001 0.320 \0.001
Creatinine (3.13) 1.938 \0.001 1.860 \0.001
DMSO2 (3.14) 1.851 \0.001 3.132 \0.001
Myo-inositol (3.285) 1.836 \0.001 1.778 \0.001
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pathological conditions like TBM. The resulting profile of
energy-associated metabolites in CSF from TBM patients
(Table 1) differs significantly from profiles of the metab-
olites associated with the controls in several ways.
3.2.1 Metabolic burst
The increased catabolism of glucose through glycolysis to
pyruvate, and its conversion to alanine and predominantly
lactate, reflects a metabolic burst as seen in the TBM CSF
profile, with the greatly elevated levels of lactate, most likely
leading to immune activation in the TB-infected microglial
cells (Nareika et al. 2005). In addition, the increased levels of
many monocarboxylates such as lactate and pyruvate, the
presence of branched-chain keto acids derived from leucine,
valine and isoleucine, and ketone bodies such as acetoace-
tate, 3-hydroxybutyrate and acetate suggests functional
down regulation of the neuron-associated monocarboxylate
Table 1 continued
PLS t test Fold change Validation
(VIP value) (p value) (d-value) (p value)
Creatinine (4.29) 1.557 \0.001 1.705 \0.001
Myo-inositol (4.05) 1.497 \0.001 1.734 0.003
Valine/isoleucine (1.01) 1.477 \0.001 0.449 \0.001
Lysine (1.73) 1.441 \0.001 0.592 \0.001
Ethanol (1.18) 1.329 0.001 0.314 0.067
Tyrosine/medication (6.90) 1.274 0.002 0.620 0.002
Phenylalanine/medication (7.42) 1.092 0.009 0.698 \0.001
Tyrosine (7.19) 1.085 0.009 0.726 \0.001
Phenylalanine (7.39) 1.074 0.010 0.578 0.003
Acetoacetate (2.30) 0.825 0.051 1.130 0.164
Choline (3.19) 0.801 0.058 0.770 0.125
Isoleucine/leucine (0.95) 0.788 0.063 0.804 0.005
Citrate (2.84) 0.730 0.085 1.284 0.121
Creatine (4.10) 0.693 0.103 1.222 0.269
Pyruvate (1.56) 0.649 0.128 0.858 0.026
Pyruvate (2.37) 0.642 0.132 0.845 0.042
Glutamine (2.47) 0.638 0.134 1.131 0.428
Mannose (5.17) 0.569 0.183 4.641 0.075
Creatine (3.05) 0.540 0.207 0.907 0.295
3-Hydroxybutyrate (2.53) 0.431 0.315 1.019 0.794
Acetate (2.08) 0.382 0.374 1.135 0.501
Betaine/myo-inositol (3.27) 0.348 0.418 1.104 0.353
3-Hydroxyisovalerate/threonine (1.33) 0.330 0.442 1.179 0.715
Ethanol (3.64) 0.306 0.477 1.074 0.513
Glutamine/medication (2.16) 0.221 0.607 0.977 0.419
Formate (8.25) 0.209 0.627 0.967 0.440
Carnitine (3.22) 0.206 0.633 1.043 0.857
Citrate (3.00) 0.203 0.637 1.032 0.362
Citrate (2.97) 0.197 0.647 1.025 0.510
Threonine (1.34) 0.183 0.671 1.080 0.672
Acetone (2.22) 0.172 0.689 1.681 0.752
Citrate (2.81) 0.164 0.703 1.064 0.685
3-Hydroxybutyrate (1.23) 0.149 0.730 1.364 0.722
Succinate (2.66) 0.133 0.758 1.103 0.640
2-Oxoglutarate (2.68) 0.111 0.797 1.060 0.456
The chemical shift, in ppm, of each identified metabolite is given in brackets
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transporter-1 (MCT-1), resulting in decreased neuronal
energy supply, which manifests in the coma-related clinical
symptoms seen in the TBM patients. Down regulation of
neuronalMCT-1 likewise promotes increased levels of these
monocarboxylic acids and ketones, which could be destined
for high-energy support to activated microglia operative in
TBM. Some pyruvate is converted to alanine by a transam-
inase reaction. The ammonia necessary for this reaction
depends on the presence of branched amino acids, leading to
an increase in the branched-chain 2-keto acids. It should be
noted that acetyl-CoA is an important precursor to the
tricarboxylic acid cycle (TCA) for energy production, not
only in the host, but is also one of the primary sources of
energy for Mtb (Savvi et al. 2008). In Mtb, formate is a by-
product of acetate production and may inhibit downstream
mitochondrial energy production in the host, limiting mac-
rophage activation.
3.2.2 Amino acids
The (BCAAs—isoleucine, leucine and valine) participate
directly and indirectly in a variety of important biochem-
ical functions in the brain, including the provision of
building blocks for the production of energy through glu-
coneogenesis under conditions of high-ATP demands as
prevails in activated microglia. BCAAs and alanine also
participate in intercellular shuttles between mitochondria in
astroglia and neurons (Sweatt et al. 2003). Likewise, a
basic aspect of neurometabolic coupling is the glutamate/
glutamine link in the glycolytic catabolism in astrocytes,
lactate production and its availability to mitochondrial ATP
production in neurons, or proposed for microglia in TBM.
Increased lysine seen in CSF from TBM patients has been
associated with mental retardation and in other motor
neuron diseases (Shaw et al. 1995); it has also been shown
to form adducts with other compounds, such as acrolein–
lysine, a marker of lipid peroxidation in childhood men-
ingitis (Tsukahara et al. 2002).
3.2.3 Creatinine
A catabolic product of creatine phosphate in muscle that is
produced at a fairly constant rate during homeostasis and
has a slow diffusion rate across the BBB. It is also corre-
lated with the CSF monoamine metabolites homovanillic
acid and 5-hydroxyindoleacetic acid, which are implicated
in neurodegenerative conditions such as depression and
schizophrenia (Agren and Niklasson 1988; Levine et al.
2000; Swahn and Sedvall 1988). Implications of perturbed
creatinine in TBM is unclear but are likely linked propor-
tionally to the progression of neuronal injury.
3.2.4 Myo-inositol
This carbohydrate is synthesized mainly de novo from
glucose in the brain. As phosphoinositides, they participate
as second messengers in numerous neurotransmitter sys-
tems and are important in signal transduction (Cordoba
et al. 1996). Myo-inositol is a glial cell marker that has
been implicated previously in activation of microglia and
astrocytes (gliosis), as well as a known pathological
response readily observed in neurodegenerative disease and
neuroinflammation (Pears et al. 2005). Thus myo-inositol is
known to be crucial in the initiation of the cascade of
events necessary for an immune response, although the
mean concentrations found in the present study do not
strongly highlight this function of myo-inositol.
3.2.5 Choline
Choline is synthesized in small amounts in the brain by
converting phosphatidylethanolamine to phosphatidylcho-
line—although its main source is dietary—and can be
oxidized to form betaine, which is a methyl source for
many reactions (e.g., conversion of homocysteine to
methionine). It is an important precursor of the neuro-
transmitter acetylcholine, which activates muscles in the
peripheral nervous system and, in excess, induces seizures
(Zimmerman et al. 2008), a common clinical symptom in
TBM. Increased choline can be related to neural membrane
breakdown, reflecting neuronal loss and gliosis in the brain.
3.2.6 Dimethyl sulfone (DMSO2)
DMSO2 is a normal constituent of human CSF, occurring in
concentrations of 0–25 lmol/L and is derived from dietary
Fig. 5 Important metabolites
that distinguish between TBM
and non-TBM cases based on
VIP values[ 1.0 and
significant univariate measures,
common to both cases and
unique to each case (increase:/
decrease; relevant to TBM
cases)
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sources, intestinal bacterial metabolism and human endog-
enous methanethiol metabolism. Metabolically, DMSO2
arises from oxidation of dimethyl sulfoxide (DMSO), and
partly from methionine metabolism (Engelke et al. 2005).
DMSO is a polar amphiphilic compound that increases
membrane fluidity (Hallows and Frank 1992), acts as a
powerful scavenger of oxygen radicals (Rosenblum 1983),
stimulates granulocytic differentiation (Watson et al. 1997)
and induces apoptosis of neuroblastoma cells (Kruman et al.
1993) and macrophages (Marthyn et al. 1998). Decreased
levels of DMSO2 in CSF can thus be postulated as being a
consequence of perturbed osmoregulation of CSF and
depletion of DMSO in response to oxidative stress, induced
apoptosis and differentiation of macrophages.
3.3 A hypothetical ‘‘astrocyte–microglia lactate
shuttle’’ (AMLS)
The pathophysiological response to neural infection by Mtb
provided the context for our interpretation of the resultant
metabolic changes outlined above. Clinical observations in
our TBM patient group include the classical profile of
encephalopathy with manifestations of seizures, involuntary
movements, fever, impaired consciousness, poor feeding
and vomiting, indicative of neuroinflammatory responses
and impaired neuronal functioning (Udani and Dastur 1970).
Concomitantly, microglial cells are likely to pose an
increased energy demand for phagocytosis of Mtb, most
likely strengthened by anaerobic glycolysis in the activated
microglia, although this response appears to be insufficient
as the energy provider for an inflammatory response
(Voloboueva et al. 2013). A present paradigm is that lactate
functions as a key intermediate in conditions of increased
energy demand, based on the notion that glycolytic and
oxidative pathways can also be operationally linked, as
opposed to alternative processes only. Lactate, the product of
the anaerobic pathway, thus becomes the substrate for the
aerobic pathway—reminiscent of the classical observation
by Carl and Gerty Cori (Cori and Cori 1928) on the con-
version of muscle glycogen to liver glycogen with lactic acid
as an intermediary stage, now commonly known as the Cori-
cycle. The intermediary role of lactate led to a postulated
lactate shuttle (Brooks 1986), even prior to the discoveries of
several classes of transport factors had been implicated in
this process in the CNS (See ‘‘Effector isoforms’’ as dis-
cussed in section S4 of the SI). Various proposals exist on the
involvement of lactate in the astrocyte’s role in cell–cell
participation under neurostress conditions, enabled also
through the syncytial network of neuronal cells within the
expansive parenchymal domain of the CNS:
(1) Initial in vitro experiments indicated that lactate is
an efficient energy substrate for neurons, particularly
during periods of intense activity. Lactate does not
cross the BBB easily, which excludes the possibility
that blood-borne lactate can be a primary source for
this energy provision, although several investiga-
tions indicate that astrocytes could release large
amounts of lactate, leading to the hypothesis of an
activity-dependent astrocyte-neuron lactate shuttle
(ANLS) for the supply of energy substrates to
neurons (Pellerin et al. 1998). Although the ANLS
hypothesis provides an important existing paradigm
on energy provision to neurons, alternative views on
activated (Patel et al. 2014) as well as resting
neurons (reviewed by Dienel and McKenna 2014)
also strongly prevails, and provides considerable
scope for alternative investigations on hypothesis
testing.
(2) Lactate is produced continuously under fully aerobic
conditions in mammalian skeletal muscle, especially
during exercise when rates of glycogenolysis and
glycolysis are elevated, with active skeletal muscles
being capable of lactate removal, mainly via oxida-
tion, from which an intracellular lactate shuttle (ILS)
has been postulated (Brooks 2002). Investigations
with primary cultures from rat cortex and hippo-
campus, including immunohistochemistry and
immunoprecipitation techniques, indicated that
monocarboxylate transporter-2 and lactate dehydro-
genase are co-expressed in the mitochondria of
cultured neurons, which gave support to the concept
that in neurons, as in skeletal muscle, a mitochon-
drial ILS could be operative (Hashimoto et al. 2008).
It has thus been proposed that lactate seems to play a
critical role in neuronal survival, memory and
conditions like Alzheimer’s disease, although more
functional evidence is needed to confirm this
hypothesis (Newington et al. 2013).
(3) Most recently, a microglia–astrocyte–neuron lactate
shuttle has been proposed for microglial activation
with lipopolysaccharide (LPS) and interferon-c, as
well as in response to conditions of excitotoxicity.
Both conditions imply the participation of a four-
component constellation in which lactate is shuttling
to neurons not only from astrocytes but also from
microglia (Gimeno-Bayo´n et al. 2014). In this model,
glucose, oxidized by astrocytes and microglia, are
converted into lactate that is taken up byneurons for its
complete oxidation, while glutamine and glutamate
synaptic removal by microglia fuels the TCA cycle to
maintain mitochondrial activity and ATP generation.
Finally, lactate not only serves as a fuel source and
gluconeogenic precursor, but it also acts as a signalling
molecule (Philp et al. 2005; Hashimoto et al. 2007).
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Hashimoto and co-workers demonstrated that lactate
increased production of reactive oxygen species (ROS) and
up-regulated 673 genes, many known to be responsive to
ROS, in L6 myogenic cells. It thus appears that increased
lactate augments inflammatory gene expression.
Against this multi-paradigm background, we speculated
that the inflammatory responses and metabolic imbalances
created in the CNS following the initial phases of infection
by a pathogen, such as Mtb, should be to the advantage of
the microglia to fulfil their immune-protective function.
For this purpose we advanced the following hypothesis:
‘The host’s response to neural infection results in an
AMLS that operates in neuroinflammatory diseases, such
as TBM.’ We formulated this hypothesis on the metabolite
information on TBM in children and infants (summarized
in Table 2), with special reference to the significant
increase in lactate in all the TBM cases, as well as through
inductive reasoning (Goodacre et al. 2004) on the charac-
teristics of the cell–cell interactions and factor isoforms,
which are well-established to be operative in normal and
stress-induced conditions in the CNS (see detailed discus-
sion in section S4 of the SI).
Briefly, it is postulated that in TBM, lactate produced
through glycolysis in astrocytes participates in the acti-
vated immune response and, in association with ketones
and gluconeogenic amino acids, is collectively directed
from the neurons preferentially into microglia where it
enters the mitochondrial TCA cycle, contributing to oxi-
dative phosphorylation and hence producing high levels of
ATP and forms of ROS required for Mtb degradation.
ROS, and a multitude of factors produced by the microglia
to modulate the functions of surrounding immune cells, are
toxic to neurons and the unregulated activation of
microglia in response to stimulants, such as Mtb, propagate
neuronal injury (Block and Hong 2005) and eventual
apoptotic cell death for the over-activated microglia as well
(Liu et al. 2001).
Activation of microglia, as implied by the AMLS
hypothesis, does not, however, present a uniform process
and involves intricate interactions and feedback loops
between the microglia, astrocytes and neurons that hamper
attempts to construct basic and linear cascades of cause and
effect; TBM involves a complex integration of the
responses from the various cell types present within the
CNS, with microglia and the astrocytes as main players.
The initiating result is the infiltration of Mtb into the
subarachnoid space followed by immune activation, but
several other factors, related to age, genetic background as
well as societal factors from the environment and past
experiences, are all expected to modulate the integrated
response of this complex neuroinflammatory pathology
underlying TBM. We also propose a conceptual model,
encapsulating the AMLS hypothesis and providing a visual
representative of theoretical constructs (see Fig. S2), as
further exploration of the pathophysiological responses in
TBM aimed at fostering curiosity and stimulating new
ideas in research on this serious disease.
4 Concluding remarks
The results from the metabolomics analysis of the CSF
from TBM-infected small children, the metabolite profile
of the host response from which it is derived, and the
avenues opened by the AMLS hypothesis, provide for
further reflection and stimulus, especially for improvement
of early clinical assessment of TBM, timely introduction of
treatment and for monitoring responses to applicable
treatment regimes. Finally, despite its declining incidence
in most high-income countries, tuberculosis shows no signs
of disappearing in the near future and prevails as a major
burden of disease affecting high-risk groups, such as socio-
economically deprived individuals and especially infants
and children. This investigation indicates that a meta-
bolomics analysis of TBM is feasible and a potentially
important complementary tool in combating this devastat-
ing disease.
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